FAQ
What is OnSite-RSA?
OnSite-RSA, or Rapid Stroke Assessment, is a simple paper-based test that requires only 1-2 drops of blood to indicate and differentiate strokes in patients. It functions similar to a pregnancy test.
How is OnSite-RSA different from the current standard of care?
The standard of care is currently a CT scan, which is expensive and time consuming. The entire process from stroke onset to diagnosis with the standard route can be 6+ hours before treatment even begins. Since brain cells start to die after just 5 minutes, time is a critical factor in stroke treatment. Our device will cut the time to diagnosis down to just 15 minutes.
How is OnSite-RSA different from other point-of-care tests?
Other point-of-care diagnostic tools exist, including electromagnetic wave and blood-based tests. Cerebrotech is a company developing a visor that identifies differences in blood flow within the brain, hoping that this will identify an intracerebral hemorrhage. However, this difference in blood flow from one side of the brain to the other can be a result of a preexisting condition or previous injury and blood flow varies by individual already. Valtari Bio and Sarissa Diagnostics are each trying to create a blood test to identify biomarkers indicative of brain trauma. However, Sarissa’s simply identifies any type of ischemia, which can be caused by heart attack or cardiac arrest, concussion, or any other type of traumatic brain injury. Valtari Bio is in the process of discovering new biomarkers, but their product is in a pre-development stage.
However, as seen in the chart below, they do not provide the level of differentiation between strokes that OnSite-RSA does. We are looking to change the stroke paradigm and bring stroke patients the level of care that they deserve. Minimizing time-to-care is imperative because it increases the chances of survival, and decreases the monetary cost of recovery and disability. This saves both patients and insurance companies money long term.
Where will OnSite-RSA be distributed?
OnSite plans to sell to ambulances and hospitals, either directly or through distributors. We will interface with all its customers at trade shows and stroke conferences, using a dedicated sales and marketing force. OnSite will strengthen its position in the market by getting endorsement from key opinion leaders and leaders in stroke research. And by working in conjunction with pre-existing diagnostic tools, OnSite can easily fit into the existing standard treatment regime.
An alternative market strategy is to license OnSite-RSA to a larger point-of-care diagnostic company to complete FDA trials and market the device for us. Having the seal of approval from an established big name company will add credibility to our product, and get us to a larger market share faster.